---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-113954"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:03:19.489050+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares

## Summary
- 90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.
- Exchange closed April 25, 2024; common shares outstanding post-exchange: 40,279,414.
- Exemption from registration relied on Section 3(a)(9) of Securities Act; no commission paid.
- Counterparty is Fairmount Healthcare Fund II L.P.; conversion ratio based on existing conversion terms.
- Following exchange, 346,045 Series A Preferred and 271,625 Series B Preferred remain outstanding.

## SEC filing metadata
- accession: 0001193125-24-113954
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/0001193125-24-113954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/d787764d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-113954
- JSON: https://secwatch.observer/filing/0001193125-24-113954.json
- Plain text: https://secwatch.observer/filing/0001193125-24-113954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.